Health Reporter
Zimbabwe’s significant advancements in HIV treatment are now threatened by emerging cases of resistance to Dolutegravir (DTG), a crucial antiretroviral drug.
Currently, over 1.2 million people are on Antiretroviral Therapy (ART), representing about 90% of those living with HIV in the country. Despite these achievements, the rise in DTG resistance poses a serious challenge to the progress made in combating the disease.
Dr. Cleophas Chimbetete, Director of Training and Research at Newlands Clinic, emphasized the urgent need to discuss treatment options following third-line ART failures. He noted that while DTG remains effective, instances of resistance are increasing, necessitating a reevaluation of treatment protocols.
“We’re beginning to see resistance to Dolutegravir… now we need to start having that conversation,” he stated, highlighting the importance of continuous monitoring and adaptation of treatment strategies.
Zimbabwe’s HIV treatment guidelines, which align with World Health Organization (WHO) recommendations, involve a tiered approach: starting with first-line ART, moving to second-line if resistance occurs, and then to third-line ART if necessary. The introduction of third-line ART in 2015 has allowed various centers across the country to provide treatment to patients who have failed earlier lines of therapy. However, the emergence of DTG resistance calls for updated national guidelines for managing post-third-line treatment failures.
Despite the challenges posed by DTG resistance, Zimbabwe remains committed to achieving the UNAIDS 95-95-95 targets: ensuring that 95% of HIV-positive individuals know their status, 95% of those diagnosed are on treatment, and 95% of those on treatment achieve viral suppression. Dr. Chimbetete stressed the need for ongoing research into DTG resistance, enhanced training for healthcare workers, and improved patient adherence to treatment regimens.
The situation underscores the importance of vigilance and adaptability in HIV treatment strategies. As Zimbabwe navigates this new challenge, the collaboration among healthcare professionals, researchers, and stakeholders will be crucial in maintaining the progress made in the fight against HIV.
Zim GBC News©2024